Gastroenterology

Patients with a delayed appendicitis diagnosis had 1.23 times increased hospital care costs, and Black patients had a greater increased cost than White patients.

Findings demonstrate a similar postoperative safety profile for both tofacitinib and biologics in patients with medically refractory ulcerative colitis undergoing colectomy.

Findings highlight the safety and efficacy of switching from originator to biosimilar adalimumab, which also showed favorable results in adalimumab-naïve patients with IBD.

Findings highlight the negative impact of bowel urgency and bowel urgency-related accidents on the daily lives of patients with UC and CD.

In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.

In part 4 of our 5-part discussion, experts discuss how to navigate conversations about risk factors and symptoms surrounding CRC.

In part 3 of our 5-part discussion, experts discuss the importance of screening among younger patient populations and strategies to encourage screening in patient populations susceptible to nonadherence.

In part 2 of our 5-part discussion, experts discuss challenges they face getting patients to engage in screening and how to effectively discuss screening with patients.

In part 1 of our 5-part discussion, experts discuss recent screening recommendation updates and the advent of new screening modalities.

The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.

Qazi discusses the impact of having standardized definitions and treatment approaches for pouchitis and inflammatory conditions of the pouch.

The first quarterly issue of 2024 reviews a promising JAK inhibitor for acute severe ulcerative colitis, fenofibrates in PBC, new recommendations from the AGA, and a next generation multi-target DNA stool test for detecting colorectal cancer.

Recent recommendations from the AGA may help gastroenterologists manage the rising rate of pouchitis with the aid of clinical evidence.

Qazi discusses a review of the use of fenofibrate as a first-line therapy in treatment-naive patients with PBC and its implications for biochemical response.

New data suggest adding fibrate therapy to frontline PBC treatment could result in earlier and higher rates of biochemical response.

Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.

Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.

Qazi discusses a review of the BLUE-C trial and explains the rise of noninvasive CRC screening and surveillance options, but highlights the need for colonoscopy nonetheless.

As clinicians work to improve CRC screening rates, a promising new test has shown favorable accuracy in detecting cases.

The post-hoc analysis found tenapanor significantly improved weekly scores for abdominal pain, discomfort, and bloating, as measured by the Abdominal Score.

A hypothetical triennial blood-based screening test meeting Centers for Medicare and Medicaid Services coverage criteria was cost-effective versus no screening but not compared to FIT, sDNA-FIT, or colonoscopy.

Findings highlight non-inferiority for major morbidity and reduced detection of grade B or C POPF among patients who did not receive prophylactic passive abdominal drainage.

Results showed the cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions.

A new study suggests a next-generation stool DNA test from Exact Sciences has improved sensitivity for colorectal cancer and precancerous lesions but lower specificity than FIT.

Test your knowledge of the AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases with this clinical quiz!